Previous close | 16.98 |
Open | 16.74 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 16.06 - N/A |
52-week range | 11.90 - 19.06 |
Volume | |
Avg. volume | 2,923 |
Market cap | 4.959M |
Beta (5Y monthly) | 0.84 |
PE ratio (TTM) | 1.32 |
EPS (TTM) | 0.13 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
GROUP REVENUES UP 18.7% WITH OTHER ACCELERATORS UP 51.1% REBIT POSITIVE FOR FY23 WITH OTHER ACCELERATORS REBIT ALMOST QUADRUPLING MEDIUM TERM GUIDANCE REITERATED Louvain-la-Neuve, Belgium, 21 March 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2023 financial year. (EUR 000)FY 2023FY 2022VarianceVariance %Total Net Sales428 717361 27067 44718.7% Proton Therapy229 065 218 76110 3044.7% Other Accelerator
Louvain-la-Neuve, Belgium, March 19, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, announced today it has signed a contract for the installation of a Be-Efficient electron beam irradiation solution equipped with two Rhodotron® accelerators in Germany. This Be-Efficient electron beam solution includes two Rhodotron® accelerators, a Beagle® production line control system and a
PanTera’s continues to deploy its strategy to become a market leader into the production and distribution of Ac225 Mol, Belgium, March 14, 2024: PanTera, the Belgian radioisotope producer created as a joint venture by IBA and SCK CEN with the primary goal to secure large-scale production of actinium-225 (225Ac), today announces the signing of a strategic supply contract with an undisclosed partner. This second supply agreement from PanTera underscores its commitment to enabling the advancement o